Review ArticleReview

Targeting PP2A for cancer therapeutic modulation

Halle Ronk, Jared S. Rosenblum, Timothy Kung and Zhengping Zhuang
Cancer Biology & Medicine October 2022, 19 (10) 1428-1439; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0330

Abstract

Protein phosphatases play essential roles as negative regulators of kinases and signaling cascades involved in cytoskeletal organization. Protein phosphatase 2A (PP2A) is highly conserved and is the predominant serine/threonine phosphatase in the nervous system, constituting more than 70% of all neuronal phosphatases. PP2A is involved in diverse regulatory functions, including cell cycle progression, apoptosis, and DNA repair. Although PP2A has historically been identified as a tumor suppressor, inhibition of PP2A has paradoxically demonstrated potential as a therapeutic target for various cancers. LB100, a water-soluble, small-molecule competitive inhibitor of PP2A, has shown particular promise as a chemo- and radio-sensitizing agent. Preclinical success has led to a profusion of clinical trials on LB100 adjuvant therapies, including a phase I trial in extensive-stage small-cell lung cancer, a phase I/II trial in myelodysplastic syndrome, a phase II trial in recurrent glioblastoma, and a completed phase I trial assessing the safety of LB100 and docetaxel in various relapsed solid tumors. Herein, we review the development of LB100, the role of PP2A in cancer biology, and recent advances in targeting PP2A inhibition in immunotherapy.

keywords

Introduction

In 1949, nitrogen mustard (mechlorethamine) became the first chemotherapeutic agent approved by the U.S. Food & Drug Administration, which was rapidly followed by a wave of chemotherapy development1. Classic anti-cancer strategies aimed at actively killing cancer cells include alkylating agents that generate crosslinks in DNA and trigger repair mechanisms to induce apoptosis, antimetabolites that severely disrupt nucleic acid synthesis, and alkaloids that interfere with microtubule polymerization/depolymerization and halt mitosis2.

Continued investigations have since revealed mutations in canonical signaling pathways that frequently drive tumorigenesis, such as the Hippo pathway or Wnt/β-catenin signaling3. Targeting these pathways via small molecule inhibitors or monoclonal antibodies has been a focus of more contemporary approaches to cancer treatment. Combining some of these neoadjuvant approaches with standard-of-care chemotherapy or radiotherapy appears to “sensitize” tumor cells to treatment. Negative regulation of protein phosphatase 2A (PP2A) as an adjuvant therapy has demonstrated such chemo- and radio-sensitizing effects4.

PP2A, a serine/threonine phosphatase composed of 3 distinct subunits—65-kDa PP2A-A (scaffold subunit), 55-kDa PP2A-B (regulatory subunit), and 37-kDa PP2A-C (catalytic subunit)—constitutes 0.2%–1.0% of the total protein content in mammalian cells and has been implicated in the regulation of diverse cellular processes, including signal transduction, cell cycle progression, DNA replication, gene transcription, and protein translation5–8. Whereas the PP2A-A and -C subunits exist in only 2 isoforms, the B regulatory subunit exists in many more9. This isoform diversity enables a multitude of holoenzyme assembly combinations, thus partially explaining the diverse cellular functions of PP2A (Figure 1).

Figure 1
Figure 1

PP2A holoenzyme. (A) Schematic representation of the PP2A holoenzyme, which consists of 3 subunits: a core dimer scaffold A subunit, a regulatory B subunit, and a catalytic C subunit. The scaffold A and catalytic C subunits are encoded by 2 distinct genes, α and β. The regulatory B subunits are classified into 4 unrelated families, each encoded by multiple genes: B (PR55), B′ (PR56/61), B″ (PR48/59/72/130), and B’″ (PR93/110 or striatin). Genetic information was obtained from the UniProt protein sequence database [https://www.uniprot.org/ (accessed on May 1 2022)]. (B) Crystal structure of PP2A bound to PP2A phosphatase activator and ATPγS (PDB 4LAC)10, with PP2A-A depicted in orange, PP2A-B depicted in green, and PP2A-C depicted in purple. (C) Crystal structure of PP5 bound to LB100, showing LB100 coordinating with metal ions and key residues at the PP5 catalytic site (PDB 5WG8)11. PP2A-C and PP5-C share a common catalytic mechanism11. Thus, the interaction between PPP5 and LB100 may provide insight into the interaction between PP2A and LB100.

Initial attempts at targeting PP2A used cantharidin, a naturally occurring compound secreted by blister beetles of the genus Epicauta chinensis12. Cantharidin has been used in traditional Chinese medicine for centuries, and is associated with bone marrow suppression and urinary tract toxicity13. Norcantharidin, the demethylated analogue of cantharidin, was first extracted from the Spanish fly Mylabris and was later synthesized in a laboratory setting14,15. Further modifications of norcantharidin led to the production of LB100, a synthetic, water-soluble, small-molecule PP2A competitive inhibitor4. Since its invention, LB100 has seen broad applications in cancer treatments. Preclinical success has led to new clinical trials of LB100 adjuvant therapies, including a phase I trial in extensive-stage small cell lung cancer (SCLC) [National Library of Medicine (NLM), NCT04560972], a phase I/II trial in myelodysplastic syndrome (NLM, NCT03886662), a phase II trial in recurrent glioblastoma (NLM, NCT03027388), and a completed phase I trial in various relapsed solid tumors (NLM, NCT01837667)16–19.

Previous reviews have examined LB100 adjuvant therapies in adult and pediatric nervous system tumors, including glioblastoma, pheochromocytoma, medulloblastoma, diffuse intrinsic pontine glioma, and neuroblastoma20. Others have focused on LB100 treatment in systemic solid tumors, including breast cancer, ovarian carcinoma, hepatocellular carcinoma, pancreatic cancer, and sarcoma4. Here, we provide an update on LB100 translational studies and insights gained from recent bench-side investigations of LB100 as a modulator of immunotherapy (Table 1).

View this table:
Table 1

Overview of reviewed preclinical studies on LB100. Studies reflect a review of the literature as of May 1, 2022.

LB100: a modulator of immunotherapy

Glioblastoma

Glioblastoma (GBM), a malignant tumor derived from glial cells or their precursors, is the most common primary brain tumor among adults33. GBM is characterized by highly aggressive behavior and poor prognosis, with a median overall survival of 15–23 months and a 5-year survival rate below 6%33. Standard-of-care treatment involves maximal safe surgical resection, radiation therapy, and concomitant temozolomide (TMZ) treatment34. Despite rigorous research and exploration of new chemotherapeutic agents, minimal progress has been made in extending life expectancy or decreasing the tumor recurrence rate among patients with GBM.

Immunotherapy has recently emerged as a potential new treatment for GBM35. The blood-brain barrier (BBB) was previously thought to severely limit the entry of immune cells into the central nervous system (CNS), thus delaying the application of immunotherapy to CNS tumors36. This dogma has since been challenged by an improved understanding of immune cell trafficking in the CNS gained through findings indicating that T cells can effectively penetrate the BBB, and that the BBB is often broken down in brain tumors, thus increasing permeability to immune cells37–40. As a result of these new data, interest in immunotherapy for CNS tumors has been reinvigorated, primarily in 2 major fronts: chimeric antigen receptor (CAR)-engineered T cells and immune checkpoint inhibition.

Several challenges preclude the successful use of CAR-T cells, which are currently designed against specific tumor neoantigens and are injected either centrally or peripherally for trafficking to CNS tumors in the treatment of GBM. These challenges include 1) the limited penetration of CAR-T cells into solid tumors and 2) their suboptimal activation within immunosuppressive tumor microenvironments41. PP2A has been identified as an independent negative regulator of CD8+ cytotoxic T cell effector function42. Because CAR-T cells are CD8+ T cells with engineered antigen specificity, PP2A modulation can be exploited in CAR-T therapy with the goal of improving CAR-T efficacy. To this end, Cui et al.21 combined LB100 with CAR-T therapy against carbonic anhydrase IX (CAIX) in mice carrying U251-Luc glioma xenografts. The combination significantly increased tumor-infiltrating lymphocytes (P < 0.05) and prolonged mouse survival compared to untreated controls (P < 0.001)21. These results suggest that LB100 may be a helpful adjuvant for immunotherapy by augmenting cytotoxic T cell function and recruiting host immune cells to tumors.

Other studies have combined LB100 with immune checkpoint inhibitors. Programmed death-1 (PD-1), a class of receptors expressed on T cell surfaces, plays an important role in maintaining immune tolerance to self-antigens43. Tumor cells aberrantly expressing PD-1 ligand (PD-L1) can prevent T cell activation and escape the host immune system43. When used as monotherapy for GBM, PD-1 blockade has not shown clinical benefit44. This failure may be partly attributable to the low basal PD-L1 expression in tumors, given that less than 3% of GBM cells express PD-L145. However, Maggio et al.22 reported significantly greater survival in syngeneic mice bearing GL261-Luc tumors receiving combination LB100 and PD-1 treatment compared with monotherapy alone (P < 0.05). Further, tumors regressed completely in 25% of mice receiving combination therapy but not in mice in either monotherapy group22. These studies suggest that LB100 may aid in extending immunotherapy to GBM management via immune checkpoint modulation.

SCLC

SCLC constitutes approximately 15% of all lung cancer diagnoses and is characterized by a high proliferative rate, early metastasis, and poor prognosis46. Standard-of-care treatment incorporates radiation with platinum-based chemotherapy46. Mirzapoiazova et al.23 combined LB100 and carboplatin treatment in mice with SCLC subcutaneous xenografts and observed significantly smaller tumor sizes than those in the vehicle control group (P < 0.001). Although combination therapy, compared with carboplatin alone, provides only a modest tumor size reduction, it has been found to increase carboplatin uptake into tumor cells (P < 0.001)23. Later studies examined the efficacy of concomitant treatment with LB100, the PD-1 checkpoint inhibitor atezolizumab, and a PD-L1 small molecule inhibitor in vitro23. In H446 SCLC spheroids plated in the presence of T cells and treated with this triple therapy, destruction of the tumor spheroids, infiltration by activated T cells, and increased tumor cell cytotoxicity have been observed23. These encouraging results suggest that LB100 may have a role as an adjuvant for SCLC treatment that enhances host immune cell anti-tumor activity.

Triple-negative breast cancer (TNBC)

TNBC is a subset of breast cancer that lacks the classic progesterone receptors, estrogen receptors, and HER2 amplification, which are targeted by common endocrine therapies47. Consequently, TBNC is associated with poorer outcomes, earlier relapse, and poor response to conventional therapy, yet with high susceptibility to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis47,48. TRAIL selectively induces the extrinsic apoptotic pathway, resulting in the downstream activation of procaspase-8 and the executioner caspases -3, -6, and -749. PP2A promotes TRAIL resistance by attenuating the phosphorylation and activation of procaspase-850. Therefore, inhibition of PP2A may overcome TRAIL resistance and promote tumor cell death. Supporting this hypothesis, Uddin et al.24 demonstrated that LB100 monotherapy results in significantly lower tumor volume in mice bearing MB468 TNBC tumor xenografts than in untreated controls. These results suggest that LB100 may serve as a novel therapy for TNBC by overcoming PP2A-associated apoptotic resistance.

Colorectal cancer (CRC)

CRC arises from neoplastic epithelial cells of the large intestine and is responsible for approximately 2 million new cases and 1 million deaths reported annually worldwide51. Local resection is the mainstay of treatment, but extracolonic metastases occur in approximately 25% of cases and require systemic chemotherapy51. Given the rapid resistance to chemotherapy, new therapeutic targets are needed to improve patient outcomes.

One potential target is the DNA mismatch repair (MMR) pathway. Defective MMR occurs in approximately 15% of sporadic CRC cases, and patients with defective MMR have a more favorable prognosis than those without defective MMR52. Defective MMR is typically associated with mutations or epigenetic inactivation in one of the 2 major MMR genes, MLH1 and MSH253. Mutations in either gene lead to high-frequency microsatellite instability (MSI)54. Yen et al.25 found that deletion of the Ppp2r1a gene, which encodes PP2A-A, in murine Lgr5+ intestinal crypt cells in vitro leads to MMR-deficient genetic signatures and positive MSI assay results. These findings have been corroborated in humans: CRC data from The Cancer Genome Atlas Project has revealed that MSI is associated with diminished mRNA and protein levels of PPP2R1A25. These data suggest that PP2A plays a role in maintaining normal MMR, and aberrant regulation of PP2A is associated with MSI. The induction of MSI in CRC leads to (1) more frequent genetic errors during active transcription and (2) translation of abnormal proteins, called neoantigens, which can be targeted by classic anti-cancer therapies52. This targetability is clinically meaningful because MSI CRC has a more favorable prognosis than non-MSI CRC52.

To clarify the mechanism triggering MSI, Yen et al.25 examined the histology of mice bearing syngeneic CT26 CRC tumors and found that PP2A-deficient mice show more tumor-infiltrating cytotoxic T cells than PP2A-wildtype mice. They hypothesized that Ppp2r1a knockdown converts microsatellite stable “cold” tumors that escape immune recognition to MSI “hot” tumors that attract immune cells by increasing tumor neoantigen expression25. To this end, the authors identified 270 missense transcripts, corresponding to 220 genes, shared by 3 PP2A-deleted tumor samples but not found in any PP2A-wildtype tumor samples25,55. These results suggest that PP2A inhibition increases genetic errors in cancer cells via MSI, increased tumor neoantigens, and subsequent cytotoxic T cell attraction in CRC25. Further, PP2A inhibition specifically enhances the immune response against tumor neoantigens to the point of overcoming the checkpoint inhibition commonly used by tumor cells to escape the host immune system25. Overall, the changes caused by PP2A inhibition promote MSI in CRC, thus improving targeting against tumors.

Later studies examined the response to LB100 in mice carrying syngeneic CT26 colorectal cancer, MC38 adenocarcinoma, 4T1 triple-negative breast cancer, and Pan18 pancreatic cancer25. After co-treatment with LB100 and anti-PD-1, these syngeneic mice demonstrate MLH1 protein loss, greater MSI frequency, and significantly lower tumor volume than controls (P = 0.01)25. Together, these data indicate an exciting new role of LB100 as a promoter of neoantigen expression and immune activation in various solid neoplasms.

One recent CRC clinical trial has raised the question of whether combining LB100 and PD-1 blockade might further increase the efficacy of immunotherapy in human CRC. This phase II clinical trial used single agent dostarlimab, an anti-PD-1 monoclonal antibody, in patients with MMR-deficient stage II or III rectal adenocarcinoma (NCT, NCT04165772)56,57. Remarkably, all 12 study participants demonstrated complete tumor regression at 6 months57. Future clinical trials might combine LB100 and anti-PD-1, given the success achieved in preclinical models25.

Updates: LB100 as a chemo-sensitizer

Osteosarcoma (OS)

OS is the most common primary malignant bone tumor and the third most common cancer in adolescence58. OS treatment comprises maximal tumor resection and a standard chemotherapy cocktail incorporating methotrexate, doxorubicin, cisplatin, and ifosfamide58. Even when maximal surgical resection is achieved, approximately 80% of patients have been found to develop metastases, thus spurring a search for new chemo-agents that can effectively target metastatic OS59. In mice with 143B OS tumor xenografts, Zhang et al.26 have shown that LB100 and cisplatin combination therapy, compared with cisplatin or LB100 alone, greatly decreases OS tumor growth (P < 0.05). Further, only 20% of mice in the combination cohort developed pulmonary metastases as compared with 80% in the cisplatin alone group and 100% in the LB100 alone group26. Histologic analysis indicated that combination therapy increased levels of phosphorylated checkpoint kinase-1 (Chk1) and decreased levels of phosphorylated p5326. LB100 is likely to attenuate p53 activation and promote Chk1-mediated G1/S arrest in response to chemotherapy-induced DNA damage, thus facilitating inappropriate entry into mitosis and causing cell death through mitotic catastrophe.

Mucoepidermoid carcinoma (MEC)

MEC is a rare malignancy that arises from the salivary glands27. The treatment for high-grade MEC involves surgical resection, although radiotherapy and chemotherapy are used intermittently27. Interestingly, preclinical models have shown that some chemo-reagents can increase PP2A activity, a response associated with MEC tumor progression60. For example, Liu et al.27 have shown that MEC cells treated with cisplatin in vitro, compared with untreated tumor cells, exhibit greater PP2A activity (116.7% that of control), as measured by phosphatase detection assays, whereas co-treatment with LB100 and cisplatin decreases PP2A activity to 85% of control levels27. This decrease in PP2A activity is clinically significant, because it has been found to correlate with diminished tumor burden in in vivo27. Interestingly, because decreasing PP2A below ∼70% of wild-type activity causes dramatic cytoskeletal changes and apoptosis in healthy and tumor cells alike, eliciting a further decrease would not be an appropriate therapeutic target61. Mice carrying subcutaneous UM-HMC1 MEC xenografts showed significantly lower tumor volume after 28 days of combination therapy than either monotherapy (P < 0.05)27. Thus, elevated PP2A levels in MEC may be associated with higher tumor burden, but adjuvant LB100 therapy reverses this trend.

Esophageal squamous cell carcinoma (ESCC)

ESCC, the sixth leading cause of cancer death worldwide, is an aggressive malignancy arising from the esophagus62. Cytotoxic chemotherapies such as paclitaxel are mainstays of treatment63. Paclitaxel binds the β-subunit of tubulin, thus preventing microtubule depolymerization and inducing arrest at G2/M phase64. Despite the success of paclitaxel, eventual resistance is inevitable. Song et al.28 observed that resistance to a nanoparticle-bound paclitaxel (nab-PTX) developed in 3 ESCC tumor lines in vitro and was associated with greater PP2A expression and stabilization of the anti-apoptotic protein MCL1. Further, this study showed that LB100 treatment attenuated PP2A expression and decreased MCL1 protein levels (P < 0.001)28. In vivo, mice bearing nab-PTX naive KYSE150 ESCC tumor cells have been found to be unaffected by LB100 monotherapy, whereas mice carrying nab-PTX resistant DR150 ESCC tumor cells display significant tumor growth inhibition after LB100 administration (P < 0.05)28. Thus, LB100 may be used to overcome tumor cell resistance to anti-microtubule agents.

Acute myelogenous leukemia (AML)

Leukemias are a diverse group of hematologic malignancies that arise from abnormal lymphocytes. AML accounts for 80% of adult acute leukemia cases65. Treatment involves co-administration of an anthracycline plus a cytarabine, followed by allogeneic stem cell transplantation66. LB100 has shown promise as a monotherapy for AML in preclinical models. In vitro, Hu et al.29 observed that LB100 monotherapy significantly increased the proportion of SKM-1 AML cells in G2/M phase from 13.4% to 31.5%, thus indicating an increased number of cells arrested in the radio- and chemo-sensitive mitotic phase of the cell cycle. Such mitotic catastrophe represents a form of apoptosis. The potential of LB100 to function as a chemosensitizer for the anthracycline daunorubicin has also been investigated. Compared with monotherapy, the combination has been found to significantly enhance cytolysis in SKM-1 AML cells and 3 primary AML patient samples in vitro (P < 0.01)29. The underlying mechanism is likely to be associated with LB100-induced upregulation of the microRNA miR-181b-1, thereby resulting in downregulation of the anti-apoptotic factor Bcl-229. Thus, treatment of AML cells with LB100 promotes mitotic catastrophe and apoptosis.

Chronic myelogenous leukemia (CML)

CML is defined by the presence of the Philadelphia chromosome (BCR-ABL1 fusion gene)67. CML treatment is based on tyrosine kinase inhibitors, which antagonize the constitutively active BCR-ABL tyrosine kinase produced by the Philadelphia chromosome67. A combination of LB100 and the tyrosine kinase inhibitor dasatinib in a transgenic mouse model of CML has been found by Lai et al.30 to result in significantly fewer BCR-ABL transcripts than those in control mice (P < 0.01). Further, combination therapy has been found to confer a survival benefit over dasatinib monotherapy (P = 0.018) and vehicle-treated mice (P = 0.001)30.

One hypothesis potentially explaining CML relapse is persistence of leukemic stem cells, which are maintained by BCR-ABL-associated signaling pathways, such as the Wnt/β-catenin pathway67. Mechanistic investigations have suggested that PP2A inhibition plays a role in CML stem cell renewal by modulating Abelson helper integration site-1 (AHI-1)30. AHI-1 directly interacts with PP2A and β-catenin, and mediates their interaction67. In the presence of functional PP2A, β-catenin is dephosphorylated and spared from ubiquitin-proteasome-mediated degradation68. When PP2A is inhibited, β-catenin does not associate with AHI-1 and remains phosphorylated30. These events lead to the degradation of β-catenin and subsequent inhibition of downstream signaling30. Thus, PP2A inhibition disrupts AHI-1-mediated signaling pathways and consequently allows LB100 to target cancer stem cells in CML.

Updates: LB100 as a radio-sensitizer

Meningioma

Meningiomas represent more than 36% of all primary CNS tumor diagnoses and arise from the neural crest belonging to the bony dura, leptomeninges, or brain surface33,69. Treatment involves surgical resection or radiation for non-resectable tumors70. Ho et al.31 investigated concurrent LB100 and radiotherapy in 3 atypical and anaplastic meningioma cell lines in vitro: IOMM-LEE, GAR, and CH-157. Combination therapy has been found to induce cell death by mitotic catastrophe and to trigger cell-cycle arrest in G2/M phase as a result of persistent unrepaired DNA damage31. Further, IOMM-LEE-bearing mice demonstrate a survival benefit when treated with combination therapy vs. radiation alone or LB100 monotherapy (P < 0.05)31. These results illustrate a novel role of LB100 chemotherapy for meningiomas.

Chordoma

Chordomas are rare, aggressive, locally invasive malignant bone tumors that are remnants of the embryologic notochord and arise within the axial skeleton71. Treatment consists of en bloc excision with postoperative radiotherapy71. Treatment of U-CH1 chordoma cells with LB100 and radiation dual therapy in vitro has been found by Hao et al.32 to lead to more cells in the radiation-sensitive G2/M phase of the cell cycle. In mice bearing U-CH1 subcutaneous xenografts, combination therapy has been found to severely attenuate tumor growth with compared to the control group (P = 0.028), LB100 monotherapy (P = 0.0014), and radiation alone (P = 0.0273) groups32. Histology performed on these mice revealed the presence of aberrant multinucleated tumor cells after LB100 treatment, suggesting that PP2A is essential for mitosis32. Thus, LB100 promotes chordoma susceptibility to radiotherapy by inducing mitotic catastrophe.

Discussion

Protein kinases and phosphatases are key targets in the development of modern anti-cancer therapies, yet their success has been tempered by toxicities affecting the heart, lungs, liver, kidneys, thyroid, skin, blood coagulation, gastrointestinal tract, and nervous system72,73. Okadaic acid, a lipophilic marine toxin produced by several species of phytoplankton inhibits multiple protein phosphatases (PPs)—PP1, PP2A, PP2B, PP4, and PP5—and is associated with various systemic toxicities including cytotoxicity through apoptosis induction, neurotoxicity associated with tau protein hyperphosphorylation, immunotoxicity via modifications on interleukin-1 production, embryotoxicity, and even tumor promotion74.

The broad adverse effect profile of nonselective PP inhibitors has encouraged the development of highly selective PP inhibitors in the hope that more selective agents may have less systemic toxicity but retain strong antitumor activity11. In contrast to its aforementioned historical predecessors, LB100 is a selective PP inhibitor: it is a well-known PP2A inhibitor, and new evidence suggests that it may also inhibit PP5 via the catalytic domain (Figure 1)11. PP2A-C and PP5-C share a common catalytic mechanism, as evidenced by the high structural similarity of catalytic pockets of both of these enzymes11. Interestingly, LB100 has modest selectivity (∼4-7 fold) for PP2A-C vs. PP5-C, thus reaffirming LB100 as a selective PP inhibitor11.

The mechanisms of action of LB100 against cancer include activating the host immune system, recruiting cytotoxic T cells to tumors, disrupting canonical signaling pathways that maintain cancer stem cells, promoting aberrant regulation of the cell cycle, and preventing tumor cell resistance to apoptosis (Figure 2). Perhaps the most striking effect of LB100 is its induction of dramatic cytoskeletal changes. Alterations in the phosphorylation state of cytoskeletal proteins in response to extracellular signals occur via changes in the relative activities of protein kinases and phosphatases75. PP2A is a counter-regulator of cytoskeletal kinases: it dephosphorylates cytosolic tau and MAP2, initiates microtubule depolymerization, and stabilizes filamentous actin branching, thereby promoting neurite outgrowth and dendritic cell branching75. Interestingly, PP2A may also influence the activation of CDK5, a non-cell cycle kinase involved in cytoskeletal regulation61,76. However, further investigation is needed to better characterize this relationship.

Figure 2
Figure 2

Downstream molecular events after LB100 adjuvant therapy. The schematic diagram summarizes the major downstream molecular events occurring after LB100 is administered concurrently with chemotherapy, radiation, and/or immunotherapy. Increased or decreased expression of the target proteins is indicated by a red or green arrow, respectively. The major effects of LB100 include activating the host immune system, targeting cancer stem cells through canonical signaling pathways, triggering mitotic catastrophe, and promoting tumor cell death through apoptosis.

Clinical studies have reaffirmed LB100 as an effective yet well-tolerated antitumor agent. A completed phase I trial on LB100 in patients with relapsed solid tumors has yielded promising results77. Of the 29 patients enrolled, grade 3 adverse events occurred in only 6 (20.7%) patients, whereas 10 (50%) patients achieved stable disease77. Adverse reactions included anemia, lymphopenia, decreased creatinine clearance, hyponatremia, and dyspnea77. Targeting PP2A inhibition by LB100 is thus a promising new avenue for the development of neoadjuvant cancer treatments. Currently, 3 ongoing clinical trials are investigating the utility of LB100 as an adjuvant therapy or second-line treatment for various solid and hematologic malignancies.

Grant support

This research was made possible by the NIH Medical Research Scholars Program, a public-private partnership supported jointly by the NIH and contributions to the Foundation for the NIH from the Doris Duke Charitable Foundation, the American Association for Dental Research, the Colgate-Palmolive Company, and other private donors. For a complete list, please visit the Foundation website at: http://fnih.org/what-we-do/current-education-and-training-programs/mrsp. This work was also supported partly by the Intramural Research Program at the National Cancer Institute at the NIH.

Conflict of interest statement

J.S.R. is the founder and president of NeuroSimplicity, LLC. The other authors declare no conflicts of interest.

Author contributions

The authors confirm contribution to the paper as follows: H.R. and Z.Z. conceived and designed the presented idea. H.R. and T.K. performed a literature review. H.R. and J.S.R. provided critical analysis and interpretation of selected articles. H.R. wrote the manuscript and designed the figures. J.S.R., T.K., and Z.Z. provided critical revisions. All authors approved the final version to be published.

  • Received June 15, 2022.
  • Accepted August 26, 2022.
https://creativecommons.org/licenses/by/4.0/

This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY) 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

References

  1. 1.↵
    2. Kinch MS.
    An analysis of FDA-approved drugs for oncology. Drug Discov Today. 2014; 19: 1831–5.
    OpenUrl
  2. 2.↵
    2. Schirracher V.
    From chemotherapy to biological therapy: a review of novel concepts to reduce the side effects of systemic cancer treatment. Int J Oncol. 2019; 54: 407–19.
    OpenUrlCrossRef
  3. 3.↵
    2. Sanchez-Vega F,
    3. Mina M,
    4. Armenia J,
    5. Chatila WK,
    6. Luna A,
    7. La KC, et al.
    Oncogenic signaling pathways in the cancer genome atlas. Cell. 2018; 173: 321–337.e10.
    OpenUrlCrossRefPubMed
  4. 4.↵
    2. Hong CS,
    3. Ho W,
    4. Zhang C,
    5. Yang C,
    6. Elder JB,
    7. Zhuang Z.
    LB100, a small molecule inhibitor of PP2A with potent chemo- and radio-sensitizing potential. Cancer Biol Ther. 2015; 16: 821–33.
    OpenUrlCrossRefPubMed
  5. 5.↵
    2. Ruediger R,
    3. Van Wart Hood JE,
    4. Walter G.
    Constant expression and activity of protein phosphatase 2A in synchronized cells. Mol Cell Biol. 1991; 11: 4282–5.
    OpenUrlAbstract/FREE Full Text
  6. 6.
    2. Seshacharyulu P,
    3. Pandey P,
    4. Datta K,
    5. Batra SK.
    Phosphatase: PP2A structural importance, regulation, and its aberrant expression in cancer. Cancer Lett. 2013; 335: 9–18.
    OpenUrlCrossRefPubMed
  7. 7.
    2. Reynhout S,
    3. Janssens V.
    Physiologic functions of PP2A: Lessons from genetically modified mice. Biochim Biophys Acta Mol Cell Res. 2019; 1866: 31–50.
    OpenUrlCrossRefPubMed
  8. 8.↵
    2. McCright B,
    3. Virshup DM.
    Identification of a new family of protein phosphatase 2A regulatory subunits. J Biol Chem. 1995; 270: 26123–8.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    2. Janssens V,
    3. Goris J,
    4. Van Hoof C.
    PP2A: the expected tumor suppressor. Curr Opin Genet. 2005; 15: 34–41.
    OpenUrlCrossRefPubMed
  10. 10.↵
    2. Guo F,
    3. Stanevich V,
    4. Wlodarchak N,
    5. Sengupta R,
    6. Jiang L,
    7. Satyshur KA, et al.
    Structural basis of PP2A activation by PTPA, an ATP-dependent activation chaperone. Cell Res. 2014; 24: 190–203.
    OpenUrlCrossRefPubMed
  11. 11.↵
    2. D’Arcy BM,
    3. Swingle MR,
    4. Papke CM,
    5. Abney KA,
    6. Bouska ES,
    7. Prakash A, et al.
    The antitumor drug LB-100 is a catalytic inhibitor of protein phosphatase 2A (PPP2CA) and 5 (PPP5C) coordinating with the active-site catalytic metals in PPP5C. Mol Cancer Ther. 2019; 18: 555–6.
    OpenUrl
  12. 12.↵
    2. Chen X,
    3. Lu S,
    4. Zhang Y.
    Identification and biochemical characterization of protein phosphatase 5 from the cantharidin-producing blister beetle, Epicauta chinensis. Int J Mol Sci. 2013; 14: 24501–13.
    OpenUrl
  13. 13.↵
    2. Pan M,
    3. Cao J,
    4. Fan Y.
    Insight into norcantharidin, a small-molecule synthetic compound with potential multi-target anticancer activities. Chin Med. 2020; 15: 55.
    OpenUrl
  14. 14.↵
    2. Wang G.
    Medical uses of mylabris in ancient China and recent studies. J Ethnopharmacol. 1989; 26: 147–62.
    OpenUrlCrossRefPubMed
  15. 15.↵
    2. Tu GG,
    3. Zhan JF,
    4. Lv QL,
    5. Wang JQ,
    6. Kuang BH,
    7. Li SH.
    Synthesis and antiproliferative assay of norcantharidin derivatives in cancer cells. Med Chem. 2014; 10: 376–81.
    OpenUrl
  16. 16.↵
    National Library of Medicine (U.S.). A phase Ib open-label study of LB-100 in combination with carboplatin/etoposide/atezolizumab in untreated extensive-stage small cell lung carcinoma. Identifier NCT04560972. 2021, May. https://clinicaltrials.gov/ct2/show/NCT04560972.
  17. 17.
    National Library of Medicine (U.S.). A phase 1b/2 study evaluating the safety and efficacy of intravenous LB-100 in patients with low or intermediate-1 risk myelodysplastic syndromes (MDS) who had disease progression or are intolerant to prior therapy. Identifier NCT03886662. 2019, April. https://clinicaltrials.gov/ct2/show/NCT03886662.
  18. 18.
    National Library of Medicine (U.S.). Phase II trial of LB100, a protein phosphatase 2A inhibitor, in recurrent glioblastoma. Identifier NCT03027388. 2019, January. https://clinicaltrials.gov/ct2/show/NCT03027388.
  19. 19.↵
    National Library of Medicine (U.S.). Safety, tolerability, and preliminary activity of LB-100, an inhibitor of protein phosphatase 2A, in patients with relapsed solid tumors: an open-label, dose escalation, first-in-human, phase I trial. Identifier NCT1837667. 2013, April-2017, January. https://clinicaltrials.gov/ct2/show/NCT01837667.
  20. 20.↵
    2. Bryant JP,
    3. Levy A,
    4. Heiss J,
    5. Banasavadi-Siddegowda YK.
    Review of PP2A tumor biology and antitumor effects of PP2A inhibitor LB100 in the nervous system. Cancers. 2021; 13: 3087.
    OpenUrl
  21. 21.↵
    2. Cui J,
    3. Wang H,
    4. Medina R,
    5. Zhang Q,
    6. Xu C,
    7. Indig IH, et al.
    Inhibition of PP2A with LB100 enhances efficacy of CAR-T cell therapy against glioblastoma. Cancers. 2020; 12: 139.
    OpenUrl
  22. 22.↵
    2. Maggio D,
    3. Ho WS,
    4. Breese R,
    5. Walbridge S,
    6. Wang H,
    7. Cui D, et al.
    Inhibition of protein phosphatase-2A with LB-100 enhances antitumor immunity against glioblastoma. J Neuro Oncol. 2020; 148: 231–44.
    OpenUrl
  23. 23.↵
    2. Mirzapoiazova T,
    3. Xiao G,
    4. Mambetsariev B,
    5. Nasser MW,
    6. Miaou E,
    7. Singhal SS, et al.
    Protein phosphatase 2A as a therapeutic target in small cell lung cancer. Mol Cancer Ther. 2021; 20: 1820–35.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    2. Uddin MH,
    3. Pimentel JM,
    4. Chatterjee M,
    5. Allen JE,
    6. Zhuang Z,
    7. Wu GS.
    Targeting PP2A inhibits the growth of triple-negative breast cancer cells. Cell Cycle. 2020; 19: 592–600.
    OpenUrl
  25. 25.↵
    2. Yen Y,
    3. Chien M,
    4. Wu P,
    5. Ho C,
    6. Huang KC,
    7. Chiang S, et al.
    Protein phosphatase 2A inactivation induces microsatellite instability, neoantigen production, and immune response. Nature. 2021; 12: 7297.
  26. 26.↵
    2. Zhang C,
    3. Hong CS,
    4. Hu X,
    5. Yang C,
    6. Wang H,
    7. Zhu D, et al.
    Inhibition of protein phosphatase 2A with the small molecule LB100 overcomes cell cycle arrest in osteosarcoma after cisplatin treatment. Cell Cycle. 2015; 14: 2100–8.
    OpenUrl
  27. 27.↵
    2. Liu L,
    3. Wang H,
    4. Cui J,
    5. Zhang Q,
    6. Zhang W,
    7. Xu W, et al.
    Inhibition of protein phosphatase 2A sensitizes mucoepidermoid carcinoma to chemotherapy via the PI3K-AKT pathway in response to insulin stimulus. Cell Physiol Biochem. 2018; 50: 317–31.
    OpenUrl
  28. 28.↵
    2. Song Q,
    3. Wang H,
    4. Jiang D,
    5. Xu C,
    6. Cui J,
    7. Zhang Q, et al.
    Pharmacological inhibition of PP2A overcomes nab-paclitaxel resistance by downregulating MCL1 in esophageal squamous cell carcinoma (ESCC). Cancers (Basel). 2021; 13: 4766.
    OpenUrl
  29. 29.↵
    2. Hu C,
    3. Yu M,
    4. Ren Y,
    5. Li K,
    6. Maggio DM,
    7. Mei C, et al.
    PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation. Sci Rep. 2017; 7: 2894.
    OpenUrl
  30. 30.↵
    2. Lai D,
    3. Chen M,
    4. Su J,
    5. Liu X,
    6. Rothe K,
    7. Hu K, et al.
    PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL+ human leukemia. Sci Trans Med. 2018; 10: 8735.
    OpenUrl
  31. 31.↵
    2. Ho WS,
    3. Sizdahkhani S,
    4. Hao S,
    5. Song H,
    6. Seldomridge A,
    7. Tandle A, et al.
    LB-100, a novel protein phosphatase 2A (PP2A) inhibitor, sensitizes malignant meningioma cells to the therapeutic effects of radiation. Cancer Lett. 2018; 415: 217–26.
    OpenUrl
  32. 32.↵
    2. Hao S,
    3. Song H,
    4. Zhang W,
    5. Seldomridge A,
    6. Jung J,
    7. Giles AJ, et al.
    Protein phosphatase 2A inhibition enhances radiation sensitivity and reduces tumor growth in chordoma. Neuro Oncol. 2018; 20: 799–809.
    OpenUrl
  33. 33.↵
    2. Ostrom QT,
    3. Gittleman H,
    4. Xu J,
    5. Kromer C,
    6. Wolinsky Y,
    7. Kruchko C, et al.
    CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009-2013. Neuro Oncol. 2016; 18 (suppl 5): v1–75.
    OpenUrlCrossRefPubMed
  34. 34.↵
    2. Stupp R,
    3. Mason WP,
    4. van der Bent MJ,
    5. Weller M,
    6. Fisher B,
    7. Taphoorn MJB, et al.
    Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352: 987–96.
    OpenUrlCrossRefPubMed
  35. 35.↵
    2. Yu MW,
    3. Quail DF.
    Immunotherapy for glioblastoma: current progress and challenges. Front Immunol. 2021; 12: 676301.
  36. 36.↵
    2. Bagley SJ,
    3. Desai AS,
    4. Linette GP,
    5. June CH,
    6. O’Rourke DM.
    CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges. Neuro Oncol. 2018; 20: 1429–38.
    OpenUrlCrossRefPubMed
  37. 37.↵
    2. Shechter R,
    3. London A,
    4. Schwartz M.
    Orchestrated leukocyte recruitment to immune-privileged sites: absolute barriers versus educational gates. Nat Rev Immunol. 2013; 13: 206–18.
    OpenUrlCrossRefPubMed
  38. 38.
    2. Louveau A,
    3. Smirnov I,
    4. Keyes TJ,
    5. Eccles JD,
    6. Rouhani SJ,
    7. Peske JD, et al.
    Structural and functional features of central nervous system lymphatic vessels. Nature. 2015; 523: 337–41.
    OpenUrlCrossRefPubMed
  39. 39.
    2. Goldmann J,
    3. Kwidzinski E,
    4. Brandt C,
    5. Mahlo J,
    6. Richter D,
    7. Bechmann I.
    T cells traffic from brain to cervical lymph nodes via the cribroid plate and the nasal mucosa. J Leukoc Biol. 2006; 80: 797–801.
    OpenUrlCrossRefPubMed
  40. 40.↵
    2. Karmur BS,
    3. Philteos J,
    4. Abbasian A,
    5. Zacharia BE,
    6. Lipsman N,
    7. Levin V, et al.
    Blood-brain barrier disruption in neuro-oncology: strategies, failures, and challenges to overcome. Front Oncol. 2020; 10: 563840.
  41. 41.↵
    2. Newick K,
    3. Moon E,
    4. Albelda SM.
    Chimeric antigen receptor T-cell therapy for solid tumors. Mol Ther Oncolytics. 2016; 3: 16006.
    OpenUrl
  42. 42.↵
    2. Taffs RE,
    3. Redegeld FA,
    4. Sitkovsky MV.
    Modulation of cytolytic T lymphocyte functions by an inhibitor of serine/threonine phosphatase, okadaic acid. Enhancement of cytolytic T lymphocyte-mediated cytotoxicity. J Immunol. 1991; 147: 722–8.
    OpenUrlAbstract
  43. 43.↵
    2. Sun J,
    3. Zhang D,
    4. Wu S,
    5. Xu M,
    6. Zhou X,
    7. Lu X, et al.
    Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives. Biomark Res. 2020; 8: 35.
    OpenUrl
  44. 44.↵
    2. Yang T,
    3. Kong Z,
    4. Ma W.
    PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges, and potential. Hum Vaccin Imunother. 2021; 17: 546–53.
    OpenUrl
  45. 45.↵
    2. Nduom EK,
    3. Wei J,
    4. Yaghi NK,
    5. Huang N,
    6. Kong L,
    7. Gabrusiewicz K, et al.
    PD-L1 expression and prognostic impact in glioblastoma. Neuro Oncol. 2016; 18: 195–205.
    OpenUrlCrossRefPubMed
  46. 46.↵
    2. Rudin CM,
    3. Brambilla E,
    4. Faivre-Finn C,
    5. Sage J.
    Small-cell lung cancer. Nat Rev Dis Primers. 2021; 7: 3.
    OpenUrl
  47. 47.↵
    2. Perez EA,
    3. Moreno-Aspitia A,
    4. Thompson EA,
    5. Andorfer CA.
    Adjuvant therapy of triple negative breast cancer. Breast Cancer Res Treat. 2010; 120: 285–91.
    OpenUrlCrossRefPubMed
  48. 48.↵
    2. Rahman M,
    3. Davis SR,
    4. Pumphrey JG,
    5. Bao J,
    6. Nau MM,
    7. Meltzer PS, et al.
    TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype. Breast Cancer Res Treat. 2009; 113: 217–30.
    OpenUrlCrossRefPubMed
  49. 49.↵
    2. Yuan X,
    3. Gajan A,
    4. Chu Q,
    5. Xiong H,
    6. Wu K,
    7. Wu GS.
    Developing TRAIL/TRAIL-death receptor-based cancer therapies. Cancer Metastasis Rev. 2018; 37: 733–48.
    OpenUrlCrossRefPubMed
  50. 50.↵
    2. Xu J,
    3. Xu Z,
    4. Zhou J,
    5. Zhuang Z,
    6. Wang E,
    7. Boerner, et al.
    Regulation of the Src-PP2A interaction in tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. J Biol Chem. 2013; 288: 33263–71.
    OpenUrlAbstract/FREE Full Text
  51. 51.↵
    2. Rawla P,
    3. Sunkara T,
    4. Barsouk A.
    Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol. 2019; 14: 89–103.
    OpenUrlCrossRefPubMed
  52. 52.↵
    2. Sinicrope FA,
    3. Mahoney MR,
    4. Smyrk TC,
    5. Thibodeau SN,
    6. Warren RS,
    7. Bertagnolli MM, et al.
    Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. J Clin Oncol. 2013; 31: 3664–72.
    OpenUrlAbstract/FREE Full Text
  53. 53.↵
    2. Piñol V,
    3. Castells A,
    4. Andreu M,
    5. Castellví-Bel S,
    6. Alenda C,
    7. Llor X, et al.
    Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA. 2005; 293: 1986–94.
    OpenUrlCrossRefPubMed
  54. 54.↵
    2. Poynter JN,
    3. Siegmund KD,
    4. Weisenberger DJ,
    5. Long TI,
    6. Thibodeau SN,
    7. Lindor N, et al.
    Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening. Cancer Epidemiol Biomarkers Prev. 2008; 17: 3208–15.
    OpenUrlAbstract/FREE Full Text
  55. 55.↵
    2. Wert-Carvajal C,
    3. Sánchez-García R,
    4. Macías JR,
    5. Sanz-Pamplona R,
    6. Pérez AM,
    7. Alemany R, et al.
    Predicting MHC I restricted T cell epitopes in mice with NAP-CNB, a novel online tool. Sci Rep. 2021; 11: 10780.
    OpenUrl
  56. 56.↵
    National Library of Medicine (U.S.). Study of Induction of PD-1 Blockade in Subjects with Locally Advanced Mismatch Repair Deficient Solid Tumors. Identifier NCT04165772. 2019, November. https://clinicaltrials.gov/ct2/show/NCT04165772.
  57. 57.↵
    2. Cercek A,
    3. Lumish M,
    4. Sinopoli J,
    5. Weiss J,
    6. Shia J,
    7. Lamendola-Essel M, et al.
    PD-1 blockade in mismatch repair-deficient, locally-advanced rectal cancer. N Engl J Med. 2022; 386: 2363–76.
    OpenUrlCrossRefPubMed
  58. 58.↵
    2. Misaghi A,
    3. Goldin A,
    4. Awad M,
    5. Kulidjian AA.
    Osteosarcoma: a comprehensive review. SICOT J. 2018; 4: 12.
    OpenUrl
  59. 59.↵
    2. Bruland OS,
    3. Høifødt H,
    4. Saeter G,
    5. Smeland S,
    6. Fodstad O.
    Hematogenous micrometastases in osteosarcoma patients. Clin Cancer Res. 2005; 11: 4666–73.
    OpenUrlAbstract/FREE Full Text
  60. 60.↵
    2. Bai X,
    3. Zhi X,
    4. Zhang Q,
    5. Liang F,
    6. Chen W,
    7. Liang C, et al.
    Inhibition of protein phosphatase 2A sensitizes pancreatic cancer to chemotherapy by increasing drug perfusion via HIF-1α-VEGF mediated angiogenesis. Cancer Lett. 2014; 55: 281–7.
    OpenUrl
  61. 61.↵
    2. Rosenblum JS,
    3. Pant H.
    CDK5 acts as a surveillance system in the nervous system. New Developments on Signal Transduction Research. UK: Nova Science Pub Inc. 2013:1–47.
  62. 62.↵
    2. Chen J,
    3. Kwong DL,
    4. Cao T,
    5. Hu Q,
    6. Zang L,
    7. Ming X, et al.
    Esophageal squamous cell carcinoma (ESCC): advance in genomics and molecular genetics. Dis Esophagus. 2015; 28: 84–9.
    OpenUrl
  63. 63.↵
    2. Hirano H,
    3. Kato K.
    Systemic treatment of advanced esophageal squamous cell carcinoma: chemotherapy, molecular-targeting therapy, and immunotherapy. Jpn J Clin Oncol. 2019; 49: 412–20.
    OpenUrlPubMed
  64. 64.↵
    2. Kamath K,
    3. Wilson L,
    4. Cabral F,
    5. Jordan MA.
    βIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J Biol Chem. 2005; 280: 12902–7.
    OpenUrlAbstract/FREE Full Text
  65. 65.↵
    2. Davis AS,
    3. Viera AJ,
    4. Mead MD.
    Leukemia: an overview for primary care. Am Fam Physician. 2014; 89: 731–8.
    OpenUrlPubMed
  66. 66.↵
    2. Roboz GJ.
    Current treatment of acute myeloid leukemia. Curr Opin Oncol. 2012; 24: 711–9.
    OpenUrlCrossRefPubMed
  67. 67.↵
    2. Zhou H,
    3. Mak PY,
    4. Mu H,
    5. Ma DH,
    6. Zeng Z,
    7. Cortes J, et al.
    Combined inhibition of β-catenin and Bcr–Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo. Leukemia. 2017; 31: 2065–74.
    OpenUrlCrossRef
  68. 68.↵
    2. Jamieson CHM,
    3. Ailles LE,
    4. Dylla SJ,
    5. Muijtjens M,
    6. Jones C,
    7. Zehnder JL, et al.
    Granulocyte-macrophage progenitors in blast-crisis CML. N Engl J Med. 2004; 351: 657–67.
    OpenUrlCrossRefPubMed
  69. 69.↵
    2. Okano A,
    3. Miyawaki S,
    4. Hongo H,
    5. Dofuku S,
    6. Teranishi Y,
    7. Mitsui J, et al.
    Associations of pathological diagnosis and genetic abnormalities in meningiomas with the embryological origins of the meninges. Sci Rep. 2021; 11: 6987.
    OpenUrl
  70. 70.↵
    2. Buerki RA,
    3. Horbinski CM,
    4. Kruser T,
    5. Horowitz PM,
    6. James CD,
    7. Lukas RV.
    An overview of meningiomas. Future Oncol. 2018; 14: 2161–77.
    OpenUrlPubMed
  71. 71.↵
    2. Walcott BP,
    3. Nahed BV,
    4. Mohyeldin A,
    5. Coumans JV,
    6. Kahle KT,
    7. Ferreira MJ.
    Chordoma: current concepts, management, and future directions. Lancet Oncol. 2012; 13: e69–76.
    OpenUrlCrossRefPubMed
  72. 72.↵
    2. Krause DS,
    3. Van Etten RA.
    Tyrosine kinases as targets for cancer therapy. N Engl J Med. 2005; 353: 172–87.
    OpenUrlCrossRefPubMed
  73. 73.↵
    2. Shah DR,
    3. Shah RR,
    4. Morganroth J.
    Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy. Drug Saf. 2013; 36: 413–26.
    OpenUrlCrossRefPubMed
  74. 74.↵
    2. Valdiglesias V,
    3. Prego-Faraldo MV,
    4. Pásaro E,
    5. Méndez J,
    6. Laffon B.
    Okadaic acid: more than a diarrheic toxin. Mar Drugs. 2013; 11: 4328–49.
    OpenUrlCrossRef
  75. 75.↵
    2. Hoffman A,
    3. Taleski G,
    4. Sontag E.
    The protein serine/threonine phosphatases PP2A, PP1, and calcineurin: a triple threat in the regulation of the neuronal cytoskeleton. Mol and Cel Neurosci. 2017; 84: 119–31.
    OpenUrl
  76. 76.↵
    2. Ajay AK,
    3. Upadhyay AK,
    4. Singh S,
    5. Vijayakumar MV,
    6. Kumari R,
    7. Pandey V, et al.
    Cdk5 phosphorylates non-genotoxically overexpressed p53 following inhibition of PP2A to induce cell cycle arrest/apoptosis and inhibits tumor progression. Mol Cancer. 2010; 9: 204.
    OpenUrlCrossRefPubMed
  77. 77.↵
    2. Chung V,
    3. Mansfield AS,
    4. Braiteh F,
    5. Richards D,
    6. Durivage H,
    7. Ungerleider RS, et al.
    Safety, tolerability, and preliminatry activity of LB-100, an inhibitor of protein phosphatase 2A, in patients with relapsed solid tumors: an open-label, dose escalation, first-in-human, phase I trial. Clin Cancer Res. 2017; 23: 3277–84.
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords